1 unknown. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Unknown 1 |
| Phase 2 | 1 | Unknown 1 |
Follow Refractory or Relapsed Multiple Myeloma: new trials by email Literature Review of Refractory or Relapsed Multiple Myeloma trials Research Report on Refractory or Relapsed Multiple Myeloma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| LCAR-B38M Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma LCAR-B38M CAR-T cell injection - Refractory or Relapsed Multiple Myeloma | Phase 1 / Phase 2 | Unknown | Nanjing Legend Biotech Co. | 100 | 2015-10-02 | 2023-06-12 |
Multiple Myeloma (1)
Blood Protein Disorders (1) · Cardiovascular Diseases (1) · Hematologic Diseases (1) · Hemic and Lymphatic Diseases (1) · Hemorrhagic Disorders (1) · Hemostatic Disorders (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Lymphoproliferative Disorders (1) · Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplasms, Plasma Cell (1) · Paraproteinemias (1) · Vascular Diseases (1)
Nanjing Legend Biotech Co. (1)